Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. by Friebus-Kardash, Justa et al.
RESEARCH ARTICLE Open Access
Susceptibility of BAFF-var allele carriers to
severe SLE with occurrence of lupus
nephritis
Justa Friebus-Kardash1,2* , Marten Trendelenburg3, Ute Eisenberger1, Camillo Ribi4, Carlo Chizzolini5,
Uyen Huynh-Do6, Karl Sebastian Lang2, Benjamin Wilde1, Andreas Kribben1, Oliver Witzke7, Sebastian Dolff1,7† and
Cornelia Hardt2†
Abstract
Background: Dysregulation of the B-cell activating factor (BAFF) system is involved in the pathogenesis of systemic
lupus erythematosus (SLE). Increased serum concentrations of BAFF are related to lupus nephritis and disease
activity among SLE patients. Recently, a variant of the BAFF-encoding gene, BAFF-var, was identified to be
associated with autoimmune diseases, in particular SLE, and to promote the production of soluble BAFF. The
present study aimed to assess the prevalence of BAFF-var in a cohort of 195 SLE patients and to analyze the
association of the BAFF-var genotype (TNSF13B) with various manifestations of SLE.
Methods: A cohort of 195 SLE patients from Central Europe, including 153 patients from the Swiss SLE Cohort
Study and 42 patients from the University Hospital Essen, Germany, underwent genotyping for detection of BAFF-
var allele.
Results: Of the 195 patients, 18 (9.2%) tested positive for BAFF-var variant according to the minor allele frequency
of 4.6%. The presence of BAFF-var was associated with the occurrence of lupus nephritis (p = 0.038) (p = 0.03 and
p = 0.003). Among various organ manifestations of SLE, the presence of BAFF-var was associated with the
occurrence of lupus nephritis (p = 0.038; odds ratio [OR], 2.4; 95% confidence interval [CI], 0.89–6.34) and renal
activity markers such as proteinuria and hematuria (p = 0.03; OR, 2.4; 95% CI, 0.9–6.4 for proteinuria; p = 0.003; OR,
3.9; 95% CI, 1.43–10.76 for hematuria). SLE patients carrying the BAFF-var allele exhibited increased disease activity
at study entry, as determined by the physician’s global assessment (PGA: p = 0.002; OR, 4.8; 95% CI, 1.54–14.93) and
the SLE Disease Activity Index (p = 0.012; OR, 3.5; 95% CI, 1.12–11.18). Consistent with that, the percentage of
patients treated with immunosuppressive agents at study entry was higher among those carrying the BAFF-var
allele than among those tested negative for BAFF-var (p = 0.006; OR, 3.7; 95% CI, 1.27–10.84).
Conclusions: Our results indicate an association between the BAFF-var genotype and increased severity of SLE.
Determining the BAFF-var status of SLE patients may improve the risk stratification of patients for whom the
development of lupus nephritis is more likely and thus may be helpful in the follow-up care and treatment of SLE
patients.
Keywords: BAFF-var allele, TNFSF13B, Systemic lupus erythematosus, Lupus nephritis, Disease activity, Swiss SLE
cohort study (SSCS)
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Background
Systemic lupus erythematosus (SLE) is an autoimmune
disorder that, if left untreated, can cause irreversible
damage to multiple tissues and organ systems. Renal in-
volvement, so-called lupus nephritis, is one of the most
frequent and severe organ manifestations of SLE [1, 2].
Lupus nephritis is considered to be the consequence of a
heterogeneous spectrum of autoantibodies that are a
serological hallmark of SLE [3, 4]. The most widely rec-
ognized mechanism of organ injury mediated by auto-
antibodies is the formation of circulating immune
complexes associated with activation of the complement
system [5]. However, various environmental factors on a
disease-prone genetic background appear to trigger de-
velopment of unrestricted hyperactivation of the im-
mune system, resulting in the onset of SLE [6].
In recent years, the treatment of SLE has evolved from
conventional drugs providing a general immunosuppres-
sive function to novel biological-targeting strategies, of
which belimumab is an important and successful thera-
peutic agent [7, 8]. Belimumab has been approved as a
treatment for SLE and is a human monoclonal antibody
directed against soluble B-cell activating factor (BAFF).
BAFF was considered to contribute to the pathogenesis
of SLE by enhancing the proliferation and survival of
autoreactive B cells, thereby leading to overproduction
of diverse autoantibodies [9, 10]. In support of this the-
ory, abnormal serum levels of BAFF have been detected
among SLE patients [10, 11]. Our previous study and
numerous other reports found an association between
BAFF serum concentrations, disease activity, and the oc-
currence of lupus nephritis [11–14]. In line with these
observations, clinical trials demonstrated the effective-
ness of belimumab in reducing the number of autoanti-
bodies and reducing disease activity among SLE patients
[8, 15, 16].
One possible reason for increased BAFF levels in SLE
patients seems to be genetic alterations. Thus, Steri et al.
described for the first time a functional genetic variant
of the BAFF encoding gene, tumor necrosis factor ligand
superfamily member 13b (TNFSF13B), which causes
overexpression of soluble BAFF and is associated with
an increased risk of autoimmunity [17]. BAFF-var (a
variant of TNFSF13B) is generated by an insertion-
deletion characterized by the replacement of five nucleo-
tides, GCTGT, by one, A (GCTGT→A). The BAFF-var
allele yields an alternative polyadenylation signal, which
in turn results in a shorter mRNA transcript. The bind-
ing sites for the inhibitory microRNA are missing from
this short mRNA transcript, and their absence prevents
downregulation of BAFF expression [17]. In addition the
RNA-binding protein, nuclear factor 90 (NF90), was also
found to bind selectively to the BAFF mRNA and to co-
operate with the microRNA-15a in order to suppress the
further BAFF translation [18]. In case of occurrence of
the BAFF-var allele the inhibitory action of NF90 on the
BAFF translation is omitted due to the lack of binding
sites for NF90 on the short mRNA transcript. Accord-
ingly, heterozygous carriers of the genetic variant, BAFF-
var, exhibit increased production of circulating BAFF,
larger numbers of B cells, and higher concentrations of
immunoglobulins. The prevalence of BAFF-var is not-
ably elevated among patients with autoimmune diseases,
such as multiple sclerosis, SLE, and rheumatoid arthritis.
This fact implies a link between BAFF-var variant and
susceptibility to autoimmune processes [17, 19]. How-
ever, to date the relationship between BAFF-var and SLE
disease activity in specific organs has not been
elucidated.
The goals of the current study were to investigate the
prevalence of BAFF-var among our central-European
SLE cohort consisting of 195 patients and to analyze the
association between BAFF-var and the typical clinical
and laboratory features of SLE.
Methods
Study population
The study population consisted of 195 adult patients
with SLE. All study subjects met at least 4 of 11 classifi-
cation criteria endorsed by the American College of
Rheumatology. We obtained 153 samples of whole blood
from SLE patients who were prospectively enrolled in
the Swiss SLE Cohort Study (SSCS) and 42 samples of
whole blood from SLE patients recruited at the Univer-
sity Hospital Essen. The samples were collected between
2007 and 2018 and were stored at − 80 °C before DNA
was isolated. Corresponding clinical and laboratory data
obtained at the time of entry into the SSCS or into the
Essen cohort of SLE patients were used for the further
analysis. Disease activity was estimated by the SLE Dis-
ease Activity Index (SLEDAI) and the Physician’s Global
Assessment (PGA) for the 153 patients from the SSCS
and by the SLEDAI alone for the 42 patients from the
University Hospital Essen. Patients with a SLEDAI score
lower than 6 points were considered to have inactive or
minimally active disease [20, 21]. Patient characteristics
of the current cohort are presented in Table 1.
The study was approved by the local ethics commit-
tees of the participating centers (University Hospital
Geneva, 06–100; University Hospital Lausanne, 04/07;
University Hospital Bern, KEK-BE 045/07; University
Hospital Basel, EKBB 262/06; University Hospital Essen,
12–5149-BO). All patients signed a written informed
consent.
Genotyping
Genomic DNA was isolated from 153 whole-blood sam-
ples from SSCS using the QIAamp DNA Blood Midi Kit
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(QIAGEN GmbH, Hilden, Germany) according to the
manufacturer’s instructions. For the 42 SLE patients
from the University Hospital Essen, DNA was purified
from peripheral blood leukocytes as previously described
[22]. For polymerase chain reaction (PCR), 50 ng of gen-
omic DNA was amplified in a reaction tube containing
Table 1 Demographic characteristics of 195 patients with systemic lupus erythematosus
ANA antinuclear antibodies; CNS central nervous system; dsDNA double-stranded DNA; PGA physician’s global assessment; SLEDAI Systemic Lupus Erythematosus
Disease Activity Index
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5 pmol of each primer (BAFFVRF, 5′-CTCAGAAGAC
AGCATCCCGGT-3; BAFFVRR, 5′-GAGAAGAATG
CTTGGCCTGCT-3), 1x reaction buffer, 1 U DNA Taq
DNA Polymerase (QIAGEN GmbH, Hilden, Germany)
and 200 μM of deoxyribonucleotide triphosphate (dNTP
Mix; Promega GmbH, Mannheim, Germany). Cycling
parameters were as follows: initial denaturation at 94 °C
for 2 min, 35 cycles at 94 °C for 15 s, annealing at 60 °C
for 30 s, at 72 °C for 1 min, and a final extension step at
72 °C for 7 min. PCR products were analyzed by electro-
phoresis in a 1.5% agarose gel stained with ethidium
bromide for identifying the BAFF-specific products (890
bp) for use as a template in sequencing reactions. PCR
samples were purified with the QIAquick 96 PCR Purifi-
cation Kit (QIAGEN GmbH, Hilden, Germany). Sequen-
cing reactions were performed with the BAFFVRS –5′-
TCAGATATGGAACATACTCACAT-3 primer and the
BigDye Terminator™ v1.1 Cycle Sequencing Kit (Thermo
Fisher Scientific, Schwerte, Germany), essentially as de-
scribed by the manufacturer. Sequencing products were
run on an ABI 3130XL Genetic Analyzer (Applied Bio-
systems, Foster City, CA, USA). Data analysis was per-
formed with Chromas software version 2.6.5
(Technelysium, South Brisbane, Australia).
Statistical analysis
Data are given as absolute numbers and percentages or
as means ± standard deviation. For comparisons of two
groups one-tailed Chi-square tests were carried out. The
level of statistical significance was set at p = 0.05. Statis-
tical analyses were performed with GraphPad Prism ver-
sion 6 (GraphPad Software, Inc., San Diego, CA, USA).
Results
Patient characteristics
We determined the prevalence of the TNFSF13B gene
variant, BAFF-var, in our central-European cohort of
195 SLE patients, including 153 patients from the SSCS
and 42 patients from the University Hospital Essen
(Fig. 1). Demographic and clinical data of the study co-
hort are summarized in Table 1. Most of our patients
were of Caucasian descent; 13 of the 195 patients (7%)
were Africans; and 14 (7%) were Asian. With regard to
manifestations of SLE in various organs or organ sys-
tems at the time of study entry, 75% of patients had
arthritis and 60% had hematological alterations. At study
entry, a biopsy proven lupus nephritis was observed in
71 patients corresponding to 36% of the total cohort.
Among the 71 patients, 30 patients had lupus nephritis
class IV, 10 patients had class III and 13 patients had
class V. While lupus nephritis class II was present in 13
patients and class I in one patient, respectively, lupus
nephritis class was unknown in 4 patients. Clinical signs
of renal manifestation such as proteinuria and hematuria
were present in 60 (31%) and 38 patients (20%), respect-
ively. Approximately half of our SLE cohort tested posi-
tive for anti–double stranded DNA (anti-dsDNA)
antibodies, and 72 subjects (37%) exhibited complement
consumption defined as low complement factor 3 and/
or low complement factor 4. Two scoring systems
reflecting the disease activity of SLE, the SLEDAI and
the PGA, were determined for all 153 patients from the
SSCS, whereas the SLEDAI alone was used for the 42
patients from the University Hospital Essen. The mean
SLEDAI score of the total study population estimated at
the time of study entry was 7 (±7 (0–42)), indicating
moderate disease activity. At inclusion, more than half
of patients were undergoing treatment with antimalarial
agents, and 44% required treatment with immunosup-
pressive agents. The immunosuppressants were cyclo-
phosphamide, azathioprine, mycophenolate mofetil,
mycophenolic acid, cyclosporine A, methotrexate, leflu-
nomide and rituximab.
BAFF-var genotype in SLE patients
The BAFF-var allele was detected in 18 of our 195 SLE
patients (9.2%); all 18 were heterozygous for the BAFF-
var allele. The minor allele frequency (MAF) of BAFF-
var was 0.0462 (4.6%). There was no significant differ-
ence in ethnic background between the 18 patients het-
erozygous for the BAFF-var allele and the 177 patients
who did not carry this allele (data not shown). Of the 18
SLE patients carrying the BAFF-var allele, 16 were Cau-
casians and one was of African origin. Another patient,
from South Africa, was of mixed origin.
Association of BAFF-var allele with lupus nephritis and
severity of SLE
With regard to diverse manifestations of SLE at the time
of study entry, a biopsy proven lupus nephritis devel-
oped in 10 of the 18 patients (56%) with the BAFF-var
allele and in 61 of the 177 patients (34%) who did not
carry this allele (p = 0.038; OR [odds ratio], 2.4; 95% con-
fidence interval [CI], 0.89–6.34) (Table 2). Although the
frequency of lupus nephritis was significantly higher
among patients carrying the BAFF-var allele, there were
no important differences between the two groups with
regard to other manifestations of SLE and the involve-
ment of other organs, such as inflammatory skin mani-
festations, photosensitivity, ulcers, arthritis, serositis,
hematological disorders, or central nervous system in-
volvement (Table 2). At study entry, 9 of the 18 patients
being heterozygous for BAFF-var (50%) had a protein-
uria occurring in the context of renal manifestation of
SLE that was higher than 0.3 g per 1 mg urine-
creatinine, whereas only 51 (29%) of the 177 SLE pa-
tients without the BAFF-var allele had proteinuria (p =
0.03; OR, 2.4; 95% CI, 0.9–6.4) (Table 3). Hematuria
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associated with active lupus nephritis also occurred more
frequently among carriers of the BAFF-var polymorphism
(8 of 18, 44%) than among patients without this poly-
morphism (30 of 177, 17%) (p = 0.003; OR, 3.9; 95% CI,
1.46–10.76) (Table 3). As shown in Table 3, there were no
significant differences between the study groups with re-
gard to the presence of antinuclear antibodies (ANA),
anti-dsDNA antibodies, or hypocomplementemia.
Taking into account disease activity of SLE at the time
of inclusion, patients with the BAFF-var allele exhibited
severe disease as assessed by the attending physician
(and subsequently defined as PGA ≥ 2) more frequently
(7 of 14, 50%) than did those without this allele (24 of
139, 17%) (p = 0.002; OR, 4.8; 95% CI, 1.54–14.93)
(Table 3). In addition, 14 of 18 (78%) patients carrying
the BAFF-var allele and 88 of 177 patients (50%)
negative for BAFF-var allele had a SLEDAI score of 6
or higher, defined as moderate to high disease activity
(p = 0.012; OR, 3.5; 95% CI, 1.12–11.18) (Table 3).
Consequently, the frequency of patients receiving im-
munosuppressive agents at the time of study entry
was significantly higher among carriers of the BAFF-
var allele (13 of 18, (72%) than among patients with-
out this allele (73 of 177, 41%) (p = 0.006; OR, 3.7;
Fig. 1 Location of the BAFF-var within the TNFSF13B gene encoding BAFF. a Schematic illustration of the location of BAFF-var in the three prime untranslated
region of TNFSF13B. b Nucleotide sequence alignment of the BAFF-var and wildtype allele. UTR, untranslated region; mir15a, micro ribonucleic acid-15a
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95% CI, 1.27–10.84) (Table 4). Moreover, the fre-
quency of administration of a combination of antimal-
arial drugs and immunosuppressive agents was higher
for the SLE patients carrying the BAFF-var allele (8
of 18, 44%) than for those without this allele (35 of
177, 20%) (p = 0.008; OR, 3.3; 95% CI, 1.19–8.83), as
shown in Table 4. The frequencies of administration
of steroids and antimalarial drugs alone were similar
between patients carrying the BAFF-var genotype and
those not carrying it (Table 4).
Discussion
This study found that the prevalence of the TNFSF13B
BAFF-var among German and Swiss SLE patients was
9.2%. Patients with the BAFF-var genotype were more
likely to exhibit signs of renal involvement, such as lupus
Table 2 Association of the BAFF-var allele with various organ manifestations in 195 patients with systemic lupus erythematosus
CI confidence interval; CNS central nervous system; OR odds ratio
Table 3 Association of the BAFF-var allele with routine serological parameters and disease activity of systemic lupus erythematosus
among 195 patients
ANA antinuclear antibodies; CI confidence interval; dsDNA double stranded DNA; OR odds ratio; PGA physician’s global assessment; SLEDAI Systemic Lupus
Erythematosus Disease Activity Index
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nephritis, proteinuria, and hematuria. Compared to SLE
patients who do not carry the BAFF-var allele, those car-
rying the allele displayed increased disease activity at the
time of study entry and more frequently required inten-
sive treatment with immunosuppressive agents.
Previous studies demonstrated that the frequency of
the BAFF-var allele was higher among SLE patients from
various European cohorts than among the corresponding
control populations, a finding suggesting a relationship
between the BAFF-var and SLE [17, 19]. The frequency
of BAFF-var allele carriers (9.2%) and the MAF of the
BAFF-var allele (4.6%) identified in our SLE study cohort
were in line with and support the findings of case-
control studies performed by González-Serna et al. [19].
We detected the BAFF-var allele in 7.1% of SLE patients
in our German cohort and the corresponding MAF was
3.69%. In comparison, the frequency of the BAFF-var al-
lele (4%) and the MAF (2.02%) among the healthy Ger-
man population were markedly lower. Similarly, the
prevalence of the BAFF-var allele among healthy control
subjects from another northern country (the
Netherlands) was 3.8%, and the MAF was 1.91%. Among
healthy subjects from Spain, the frequency (8.8%) and
MAF (4.2%) of the BAFF-var allele were increased; how-
ever, among the corresponding Spanish SLE cohort the
prevalence and MAF of the BAFF-var allele were even
higher than in healthy control subjects with 10.8 and
5.81%, respectively [19]. These variations are mainly due
to the previously described north-south gradient under-
lying the higher minor allele frequency of the BAFF-var
allele observed for southern European countries (Spain,
4.2%; Italy, 5.9%) than for the northern European coun-
tries (United Kingdom, 1.8%; Netherlands, 1.9%;
Germany, 2.02%) [17, 19]. No homozygous carries of the
BAFF-var allele were identified in our SLE cohort. The
finding is in line with observations of the group of Gon-
zález-Serna et al. who did not detect any homozygotes
within the control cohorts from Germany and
Netherlands and identified only one homozygous carrier
of the BAFF-var allele among 427 German SLE patients
[19]. Related to the low allele frequency of BAFF-var in
Northern Europe the appearance of carriers with homo-
zygous genotype is very rare. It is noteworthy that our
study population consisted predominantly of SLE pa-
tients from Switzerland rather than patients representing
a central-European population influenced by migration.
Hence, a low percentage of these SLE patients were of
African or Asian ancestry. These facts should be consid-
ered when the results of our study are interpreted, be-
cause they may explain why the prevalence of the BAFF-
var allele in our cohort is slightly higher compared to
the German SLE cohort reported by González-Serna
et al. [19]. However, separate analysis of the prevalence
of the BAFF-var allele among German SLE patients from
the University of Essen and patients from the SSCS
found that both subgroups exhibited the same MAF
(4%) (data not shown). A limitation of our study is a
missing second control population from Switzerland,
however we assumed a comparable genetic Caucasian
background in both study cohorts.
We focused primarily on analyzing the association of
the BAFF-var genotype with several disease manifesta-
tions of SLE. Here, our data contradict the observations
of Steri et al., who found no association between the
BAFF-var allele and clinical manifestations of SLE in 302
patients from the Sardinian SLE population [17]. In con-
trast, we demonstrated for the first time an association
between the BAFF-var allele and SLE disease activity
and renal involvement. However, the analysis of overall
362 Italian SLE patients performed by Steri et al. re-
vealed a trend towards increased occurrence of renal dis-
orders among SLE patients with the BAFF-var genotype
compared to those without supporting our data [17].
These findings are likely attributable to the fact that the
presence of the BAFF-var allele led to an increased pro-
duction of soluble BAFF, thereby resulting in sustained
Table 4 Association of the BAFF-var allele with therapy being administered to 195 patients with systemic lupus erythematosus at
study entry
CI confidence interval; OR odds ratio
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high levels of BAFF. Consistently, several studies have
found that elevated BAFF levels are linked to lupus
nephritis and exacerbation of SLE [11–14]. However,
serum concentrations of BAFF are modulated by add-
itional regulatory factors (e.g., current B-cell number,
type of immunosuppressive treatment etc.) and may vary
widely. In contrast, the BAFF-var allele is inherited and
its expression does not depend on current therapies or
other factors potentially influencing serum levels. Thus,
the presence of BAFF-var allele constitutively impairs
the downregulation of BAFF expression and results in a
predisposition to higher levels of BAFF, which are impli-
cated in the immunopathological pathway of SLE and in-
fluence the course of disease among carriers of the
BAFF-var allele. A previous study of promoter and
exon polymorphisms of the BAFF gene [23] failed to
show causality with BAFF synthesis and demonstrated
in general only a weak association with susceptibility
to SLE. However, this study did not analyze the
BAFF-var allele [23].
Interestingly, the effect of the BAFF-var allele was re-
stricted to the lupus nephritis without heightening the
frequency of other organ involvements. We hypothesize
that occurrence of the BAFF-var allele might induce the
intrarenal overexpression of BAFF besides increasing the
levels of soluble BAFF in peripheral circulation. In re-
spect to latter studies, release of BAFF by renal tubular
epithelial cells was described to contribute to the patho-
genesis of lupus nephritis in mice and humans [24–26].
Schwarting et al. showed that BAFF derived from renal
tubular epithelial cells activates production of colony
forming factor 1 via autocrine loop by binding to the
BAFF receptors located on tubular epithelial cells result-
ing in macrophage influx and creating an inflammatory
microenvironment in the affected kidneys [24]. Add-
itionally, local constitutive expression of BAFF within
the kidney promotes formation of large organized ter-
tiary lymphoid organs in lupus nephritis leading to ex-
pansion of activated B cells and plasmablasts reactive to
renal antigens [25, 26]. Otherwise, elevated intrarenal
BAFF production mediates glomerular damage in case of
lupus nephritis by inducing invasion of T cells secreting
proinflammatory cytokines as well as attracting Th17
cells [26]. Moreover, local production of BAFF by infil-
trating immune cells retains a proliferative effect on
glomerular mesangial cells through interaction with its
receptor BAFF-R following activation of protein kinase B
and consequently stimulating the development of lupus
nephritis [27].
Our results imply that it may be reasonable to stratify
SLE patients according to their BAFF-var allele status as
a genetic risk factor. On the other hand, we are aware of
the BAFF-var allele being a rare genetic variant and oc-
curring at a relatively low allele frequency. Moreover,
besides the presence of the BAFF-var allele and high
serum levels of BAFF, a range of other factors exert an
effect on the course of SLE [5, 6]. However, we believe
that the BAFF-var allele is of high clinical significance as
a promising candidate for a genetic risk marker that can
determine which SLE patients may require extended
follow-up care and intensive immunosuppressive therapy
because of the relationship between this allele and the
risk of severe SLE with renal manifestations.
Moreover, with respect to individualized therapeutic
approaches for SLE patients, we assume that knowledge
of the patient’s BAFF-var status and subsequent discrim-
ination between patients carrying this allele and those
not carrying it may be useful for making the decision
about whether to use therapeutic strategies based on
anti-BAFF. B-cell depletion therapies, such as rituximab,
may not be appropriate for carriers of the BAFF-var al-
lelic variation because of the potentially rapid restitution
of B-cells as a result of high levels of circulating BAFF
[28, 29]. Furthermore, the effects of belimumab on SLE
patients carrying the BAFF-var allele are controversial.
On the one hand, patients with the BAFF-var allele may
benefit from early treatment with belimumab, which tar-
gets BAFF overexpression. On the other hand, the pres-
ence of the BAFF-var allele may lead to a weaker
response or even resistance to belimumab, so that higher
dosages would be necessary for overcoming the overpro-
duction of BAFF. Therefore, we assume that the re-
sponse to belimumab among carriers of the BAFF-var
allele and appropriate control subjects, as well as the de-
tection of the BAFF-var allele among patients who do
not respond to belimumab, warrants investigation in fu-
ture studies.
Of importance, there are some limitations to our
study. Our cohort was small in comparison to those in-
volved in previously reported studies of the rare BAFF-
var allele and SLE. Also, we did not include a control
population from Switzerland; however, we anticipated
that both study cohorts would exhibit a comparable gen-
etic (white) background. We analyzed the association be-
tween BAFF-var allele status and disease activity scores
(SLEDAI and PGA) as unstable variables that changed,
in particular with regard to dependence on therapy. To
avoid bias, we decided to use exclusively the SLEDAI
and PGA scores captured at the time of entry into the
SSCS or into the SLE cohort from the University Hos-
pital Essen. The time points of diagnosis and study entry
were congruent at least in one third of the 195 SLE pa-
tients in our cohort. Otherwise, in consistence with data
on the association between the BAFF-var allele and dis-
ease activity at study entry, patients with the BAFF-var
allele received more-intensive treatment for SLE, with a
significantly higher frequency of immunosuppressant
administration.
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Conclusions
Our study revealed a striking association of BAFF-var al-
lele with the occurrence of lupus nephritis, renal activity
markers such as proteinuria and microhematuria and
disease activity defined by the SLEDAI and PGA at study
entry. Consequently, carriers of the BAFF-var allele re-
quired more frequently immunosuppressive treatment
than those tested negative for BAFF-var. Therefore, de-
termining the BAFF-var status of SLE patients may im-
prove the risk stratification of patients for whom the
development of lupus nephritis is more likely and thus
may be helpful in the follow-up care and treatment of
SLE patients.
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